Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022).
Amy Colson, Megan Chen, Fritha Hennessy, Joshua Gruber, Woodie Zachry, Seojin Park, Tim Holbrook
{"title":"Health care provider- and patient-reported outcomes for bictegravir/emtricitabine/tenofovir alafenamide versus other antiretroviral regimens: an observational survey in the United States (July 2021-March 2022).","authors":"Amy Colson, Megan Chen, Fritha Hennessy, Joshua Gruber, Woodie Zachry, Seojin Park, Tim Holbrook","doi":"10.1080/03007995.2025.2517692","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study compared outcomes reported by health care providers (HCPs) and people with HIV (PWH) for individuals prescribed bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus other antiretroviral therapy (ART) regimens.</p><p><strong>Methods: </strong>Data were from the Adelphi Real World HIV Disease Specific Programme, an observational, cross-sectional survey of HCPs and PWH conducted from July 2021-March 2022 in the United States. PWH were aged ≥18 years with confirmed HIV and a current ART prescription. Outcomes included HCP- and PWH-reported adherence, treatment satisfaction, quality of life (QoL), and health care resource utilization (HCRU). Subgroups for the primary analysis were based on ART regimen. Comparisons between subgroups were performed using appropriate statistical tests.</p><p><strong>Results: </strong>Sixty HCPs provided data for 600 PWH, and 249 PWH reported their experiences. Overall, 264 PWH were prescribed B/F/TAF, 281 were prescribed other single-tablet regimens or a long-acting injectable (STRs/LAI), and 55 were prescribed a multi-tablet regimen. Common HCP-reported reasons for choice of ART were viral potency and tolerability. High treatment satisfaction was reported for B/F/TAF by HCPs (61% \"very satisfied\" with B/F/TAF vs 53% with other STRs/LAI; <i>p</i> = 0.0223) and PWH (57% vs 52%, respectively; <i>p</i> = 0.3170). PWH receiving B/F/TAF reported significantly higher QoL and lower activity impairment versus PWH receiving other STRs/LAI. Adherence rates and HCRU were generally similar between groups.</p><p><strong>Conclusion: </strong>Positive HCP- and PWH-reported outcomes were seen across ART regimens. However, differences observed, including HCP-reported treatment satisfaction and PWH-reported QoL, favored B/F/TAF compared with other STRs/LAI. Findings support continued use of B/F/TAF for HIV treatment in the United States.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-13"},"PeriodicalIF":2.4000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2517692","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study compared outcomes reported by health care providers (HCPs) and people with HIV (PWH) for individuals prescribed bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus other antiretroviral therapy (ART) regimens.
Methods: Data were from the Adelphi Real World HIV Disease Specific Programme, an observational, cross-sectional survey of HCPs and PWH conducted from July 2021-March 2022 in the United States. PWH were aged ≥18 years with confirmed HIV and a current ART prescription. Outcomes included HCP- and PWH-reported adherence, treatment satisfaction, quality of life (QoL), and health care resource utilization (HCRU). Subgroups for the primary analysis were based on ART regimen. Comparisons between subgroups were performed using appropriate statistical tests.
Results: Sixty HCPs provided data for 600 PWH, and 249 PWH reported their experiences. Overall, 264 PWH were prescribed B/F/TAF, 281 were prescribed other single-tablet regimens or a long-acting injectable (STRs/LAI), and 55 were prescribed a multi-tablet regimen. Common HCP-reported reasons for choice of ART were viral potency and tolerability. High treatment satisfaction was reported for B/F/TAF by HCPs (61% "very satisfied" with B/F/TAF vs 53% with other STRs/LAI; p = 0.0223) and PWH (57% vs 52%, respectively; p = 0.3170). PWH receiving B/F/TAF reported significantly higher QoL and lower activity impairment versus PWH receiving other STRs/LAI. Adherence rates and HCRU were generally similar between groups.
Conclusion: Positive HCP- and PWH-reported outcomes were seen across ART regimens. However, differences observed, including HCP-reported treatment satisfaction and PWH-reported QoL, favored B/F/TAF compared with other STRs/LAI. Findings support continued use of B/F/TAF for HIV treatment in the United States.
期刊介绍：
Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
